VYNE Therapeutics Inc. (NASDAQ: VYNE) related to its merger with Yarrow Bioscience, Inc. Upon completion of the proposed transaction, VYNE shareholders are expected to own 3% of the combined company.
VYNE Therapeutics Inc. (NASDAQ: VYNE) related to its merger with Yarrow Bioscience, Inc. Upon completion of the proposed transaction, VYNE shareholders are expected to own 3% of the combined company.